Discovery of new Biomarkers

Acobiom (Montpellier, France) is focused on the discovery of new Biomarkers and their use in combination with drugs to improve diagnostics and treatments. These RNA/DNA biomarkers could be applied in several activities including: treatment response prediction, treatment efficiency, disease detection and classification, patient stratification, etc.

Our approach to discover new Biomarkers

Acobiom’s approach to discover new RNA/DNA Biomarkers is based on Next-Generation Sequencing (NGS), the investigation of gene expression changes, the analyses of biological phenotypes.

These Biomarkers can be applied in several activities including:

  • patient stratification,
  • treatment response prediction,
  • assessment of drug toxicity and treatment efficiency,
  • disease detection and classification,


The gene expression biomarker-based approach has been implemented by Acobiom in response to the growing need for reducing risks in drug development and improving patient outcomes for pharmaceutical companies and healthcare providers.

During the course of its R&D and service activities, Acobiom has identified dozens of Biomarkers in correlation with therapies/drugs, cognitive score/impairment, disease detection, evolution and prognosis, immune response, vaccination, infectious diseases, and pharmacogenomics.
These Biomarkers were identified in different types of tissues, organs, and for specific biological questions.

Moreover, some of its researches, collaborations or partnerships have issued scientific publications.

To obtain more information concerning the expertise of Acobiom in Biomarker discovery and Diagnostic development, in its technology know-how in genomics, pharmacogenomics, transcriptomics, bioinformatics, please download the document: « ACOBIOM Expertises »

If you need more information, please contact our Business Development department
(T: +33(0)467 419 748, Email: